Press Resease

Critical Limb Ischemia Treatment Market - Global Industry Analysis

Critical Limb Ischemia Treatment Market By Treatment (Devices and Medications): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025

Published Date: 08-Jul-2019 Category: Pharmaceutical Report Format : PDF Pages: 120 Report Code: ZMR-4340 Status : Published

Global critical limb ischemia treatment market expected to generate USD 5,390 million by 2025, at a CAGR of 8.1% between 2019 and 2025. Critical limb ischemia is a chronic disease of peripheral arteries, in which chronic inflammation allied with atherosclerosis causes abridged flow of blood and oxygen to the legs, hands, and feet.

Description

The report covers a forecast and an analysis of the global critical limb ischemia treatment market on a global and regional level. The study provides historical data for 2017 and 2018 along with a forecast from 2019 to 2025 based on revenue (USD Million). The study includes the drivers and restraints of the global critical limb ischemia treatment market along with their impact on the demand over the forecast rime period. Additionally, the report includes the study of opportunities available in the global critical limb ischemia treatment market on a global level.

In order to give the users of this report a comprehensive view of the global critical limb ischemia treatment market. We have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the critical limb ischemia treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new launch, agreements, partnerships, collaborations, and joint ventures, research and development, and regional expansion of major participants involved in the critical limb ischemia treatment market on a global and regional basis.

The study provides a decisive view of the global critical limb ischemia treatment market that is bifurcated based on treatment and region. The regional segment includes North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa.

Some major players of the global critical limb ischemia treatment market are Boston Scientific Corporation, Medtronic, Cesca Therapeutics, Pluristem Therapeutics, Abbott Laboratories, Rexgenero, Micro Medical Solutions, LimFlow, and Cardiovascular Systems.

This report segments the global critical limb ischemia treatment market into:

Global Critical Limb Ischemia Treatment Market: Drug Type Analysis

  • Devices
    • Embolic Protection Devices
    • Peripheral Dilatation Systems
      • Balloon Dilators
      • Vascular stents
  • Medications
    • Antiplatelet Drugs
    • Antihypertensive Agents
    • Lipid-lowering Agents
    • Antithrombotic Agents
    • Others

Global Critical Limb Ischemia Treatment Market: Regional Analysis

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1.    Introduction
    • 1.1.    Report description and scope
    • 1.2.    Research scope 
    • 1.3.    Research methodology
      • 1.3.1.    Market research process
      • 1.3.2.    Market research methodology
  •  
  • Chapter 2.    Executive Summary
    • 2.1.    Global Critical Limb Ischemia Treatment market, 2017–2025 (USD Million)
    • 2.2.    Global Critical Limb Ischemia Treatment Market: Snapshot
  •  
  • Chapter 3.    Global Critical Limb Ischemia Treatment Market – Industry Dynamics
    • 3.1.    Introduction 
    • 3.2.    Market Drivers
      • 3.2.1.    Rising prevalence of Limb Ischemia
      • 3.2.2.    Increasing patient preference for devices
      • 3.2.3.    Introduction of newer agents 
    • 3.3.    Market Restraints
      • 3.3.1.    Competition from generic drugs
      • 3.3.2.    High cost of surgical treatment
    • 3.4.    Opportunities 
      • 3.4.1.    Promising pipeline and approvals 
    • 3.5.    Porter’s Five Forces Analysis 
    • 3.6.    Market Attractiveness Analysis
      • 3.6.1.    Market attractiveness analysis, by Treatment
      • 3.6.2.    Market attractiveness analysis, by region
  •  
  • Chapter 4.    Global Critical Limb Ischemia Treatment Market – Competitive Landscape
    • 4.1.    Company market share analysis
      • 4.1.1.    Global Critical Limb Ischemia Treatment Market: company market share, 2018
    • 4.2.    Strategic development
      • 4.2.1.    Acquisitions & mergers
      • 4.2.2.    New therapy launch
      • 4.2.3.    Agreements, partnerships, collaborations, and joint ventures
      • 4.2.4.    Research and development and regional expansion
  •  
  • Chapter 5.    Global Critical Limb Ischemia Treatment Market – Treatment analysis
    • 5.1.    Global Critical Limb Ischemia Treatment Market: Treatment overview 
      • 5.1.1.    Global Critical Limb Ischemia Treatment Market Revenue share, by Treatment, 2018 and 2025
    • 5.2.    Devices
      • 5.2.1.    Global Critical Limb Ischemia Treatment market for Devices, 2017–2025 (USD Million)
    • 5.3.    Medication
      • 5.3.1.    Global Critical Limb Ischemia Treatment market for Medication, 2017–2025 (USD Million)
  •  
  • Chapter 6.    Global Critical Limb Ischemia Treatment Market – Regional Analysis
    • 6.1.    Global Critical Limb Ischemia Treatment Market: regional overview 
      • 6.1.1.    Global Critical Limb Ischemia Treatment Market Revenue share, by region, 2018 and 2025
    • 6.2.    North America
      • 6.2.1.    North America Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
      • 6.2.2.    The U.S.
        • 6.2.2.1.    The U.S. Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million)
      • 6.2.3.    Canada 
        • 6.2.3.1.    Canada Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
    • 6.3.    Europe 
      • 6.3.1.    Europe Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
      • 6.3.2.    UK
        • 6.3.2.1.    UK Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.3.3.    Germany
        • 6.3.3.1.    Germany Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.3.4.    France
        • 6.3.4.1.    France Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.3.5.    Rest of Europe
        • 6.3.5.1.    Rest of Europe Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
    • 6.4.    Asia Pacific 
      • 6.4.1.    Asia Pacific Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
      • 6.4.2.    China
        • 6.4.2.1.    China Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.4.3.    Japan
        • 6.4.3.1.    Japan Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.4.4.    India
        • 6.4.4.1.    India Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.4.5.    Rest of Asia Pacific
        • 6.4.5.1.    Rest of Asia Pacific Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
    • 6.5.    Latin America
      • 6.5.1.    Latin America Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
      • 6.5.2.    Brazil
        • 6.5.2.1.    Brazil Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
      • 6.5.3.    Rest of Latin America
        • 6.5.3.1.    Rest of Latin America Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
    • 6.6.    The Middle East and Africa
      • 6.6.1.    The Middle East and Africa Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
  •  
  • Chapter 7.    Company Profile 
    • 7.1.    Boston Scientific Corporation
      • 7.1.1.    Overview  
      • 7.1.2.    Financials  
      • 7.1.3.    Treatment portfolio
      • 7.1.4.    Business strategy 
      • 7.1.5.    Recent developments 
    • 7.2.    Medtronic
      • 7.2.1.    Overview  
      • 7.2.2.    Financials  
      • 7.2.3.    Treatment portfolio
      • 7.2.4.    Business strategy 
      • 7.2.5.    Recent developments 
    • 7.3.    Cesca Therapeutics
      • 7.3.1.    Overview  
      • 7.3.2.    Financials  
      • 7.3.3.    Treatment portfolio
      • 7.3.4.    Business strategy 
      • 7.3.5.    Recent developments 
    • 7.4.    Pluristem Therapeutics
      • 7.4.1.    Overview  
      • 7.4.2.    Financials  
      • 7.4.3.    Treatment portfolio
      • 7.4.4.    Business strategy 
      • 7.4.5.    Recent developments 
    • 7.5.    Abbott Laboratories
      • 7.5.1.    Overview  
      • 7.5.2.    Financials  
      • 7.5.3.    Treatment portfolio
      • 7.5.4.    Business strategy 
      • 7.5.5.    Recent developments 
    • 7.6.    Rexgenero
      • 7.6.1.    Overview  
      • 7.6.2.    Financials  
      • 7.6.3.    Treatment portfolio
      • 7.6.4.    Business strategy 
      • 7.6.5.    Recent developments 
    • 7.7.    Micro Medical Solutions
      • 7.7.1.    Overview  
      • 7.7.2.    Financials  
      • 7.7.3.    Treatment portfolio
      • 7.7.4.    Business strategy 
      • 7.7.5.    Recent developments 
    • 7.8.    LimFlow
      • 7.8.1.    Overview  
      • 7.8.2.    Financials  
      • 7.8.3.    Treatment portfolio
      • 7.8.4.    Business strategy 
      • 7.8.5.    Recent developments
    • 7.9.    Cardiovascular Systems
      • 7.9.1.    Overview  
      • 7.9.2.    Financials  
      • 7.9.3.    Treatment portfolio
      • 7.9.4.    Business strategy 
      • 7.9.5.    Recent developments

List of Figures 

1. Market research process
2. Market research methodology
3. Global Critical Limb Ischemia Treatment Market Revenue, 2017–2025 (USD Million) 
4. Porter’s Five Forces Analysis
5. Global Critical Limb Ischemia Treatment market attractiveness analysis, by treatment
6. Global Critical Limb Ischemia Treatment Market: market attractiveness analysis, by region
7. Company market share analysis, 2018
8. Global Critical Limb Ischemia Treatment Market Revenue share by Treatment, 2018 and 2025
9. Global Critical Limb Ischemia Treatment Market Revenue share by Devices, 2017–2025 (USD Million)
10. Global Critical Limb Ischemia Treatment Market revenue share by Peripheral Dilatation Systems, 2017–2025 (USD Million)
11. Global Critical Limb Ischemia Treatment Market revenue share by Embolic Protection Devices, 2017–2025 (USD Million)
12. Global Critical Limb Ischemia Treatment Market Revenue share by Medication, 2017–2025 (USD Million)
13. Global Critical Limb Ischemia Treatment Market Revenue share by Antihypertensive Agents, 2017–2025 (USD Million)
14. Global Critical Limb Ischemia Treatment Market Revenue share by Lipid-lowering Agents, 2017–2025 (USD Million)
15. Global Critical Limb Ischemia Treatment Market Revenue share by Antiplatelet Drugs, 2017–2025 (USD Million)
16. Global Critical Limb Ischemia Treatment Market Revenue share by Antithrombotic Agents, 2017–2025 (USD Million)
17. Global Critical Limb Ischemia Treatment Market Revenue share by Others, 2017–2025 (USD Million)
 


List of Tables

1. Global Critical Limb Ischemia Treatment Market: market snapshot                                                           
2. Drivers of the Global Critical Limb Ischemia Treatment Market: impact analysis 
3. Restraints of the Global Critical Limb Ischemia Treatment Market: impact analysis
4. North America Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
5. The U.S. Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
6. Canada Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
7. Europe Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
8. UK Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
9. Germany Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
10. France Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
11. Rest of Europe Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
12. Asia Pacific Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
13. China Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
14. Japan Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
15. India Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
16. Rest of Latin America Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
17. Rest of Asia Pacific Critical Limb Ischemia Treatment Market Revenue, by distribution channel, 2017–2025 (USD Million)
18. Latin America Critical Limb Ischemia Treatment Market Revenue, by distribution channel, 2017–2025 (USD Million)
19. Brazil Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
20. Rest of Latin America Critical Limb Ischemia Treatment Market Revenue by Treatment, 2017–2025 (USD Million) 
21. The Middle East and Africa Critical Limb Ischemia Treatment Market Revenue, by Treatment, 2017–2025 (USD Million)
 

Methodology

Free Analysis

Critical limb ischemia is a chronic disease of peripheral arteries, in which chronic inflammation allied with atherosclerosis causes abridged flow of blood and oxygen to the legs, hands, and feet. This, in turn, leads to chronic pain and soreness. The key factors responsible for critical limb ischemia disease include aging, as geriatric people are more susceptible to the development of these conditions, diabetes, obesity, extremely high cholesterol levels, sedentary lifestyle, smoking, and increased blood pressure. The common symptoms of critical limb ischemia disease are gangrene, ischemic rest pain, loss of tissue, etc. The growing prevalence of critical limb ischemia is expected to drive the demand for its treatment, which, in turn, is predicted to propel the growth of the critical limb ischemia treatment market globally. In the U.S., about 2 to 3 million people are suffering from critical limb ischemia. Furthermore, the growing healthcare spending and increasing number of new drug development studies are also expected to boost the development of the critical limb ischemia treatment market globally. Additionally, the growing competition among the key players operating in the global critical limb ischemia market for the development of advanced therapy is anticipated to further propel the market growth in the future.

 

The critical limb ischemia treatment market is fragmented on the basis of treatment and region. By treatment, the market is segmented into two major categories—devices and medications. On the basis of devices, the global critical limb ischemia treatment market includes peripheral dilatation systems, and embolic protection devices. The peripheral dilatation systems are further classified into vascular stents, and balloon dilators. The medications segment of the critical limb ischemia treatment market includes antihypertensive agents, antiplatelet drugs, antithrombotic agents, lipid-lowering agents, and others. In terms of growth rate, the critical limb ischemia devices segment is expected to register the highest CAGR in the global market over the forecasted time span.

North American and European regions dominated the global critical limb ischemia treatment market with substantial market shares in the year 2018. This can be attributed to the high obesity rate, growing ischemia diseases due to unhealthy lifestyles across North America. The Asia Pacific region is expected to register the highest growth in the global critical limb ischemia treatment market in the years to come, owing to the increasing awareness among the regional population about the critical limb ischemia.

Some major players of the global critical limb ischemia treatment market are Boston Scientific Corporation, Medtronic, Cesca Therapeutics, Pluristem Therapeutics, Abbott Laboratories, Rexgenero, Micro Medical Solutions, LimFlow, and Cardiovascular Systems.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social